Bicara Therapeutics Inc. ... (BCAX)
13.78
0.62 (4.71%)
At close: Feb 20, 2025, 3:59 PM
13.82
0.29%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 10.5 |
| Market Cap | 749.85M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.09 |
| PE Ratio (ttm) | -12.64 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 14.46 |
| Volume | 250,798 |
| Avg. Volume (20D) | 429,027 |
| Open | 13.16 |
| Previous Close | 13.16 |
| Day's Range | 12.96 - 13.78 |
| 52-Week Range | 11.10 - 28.09 |
| Beta | undefined |
About BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 32
Stock Exchange NASDAQ
Ticker Symbol BCAX
Website https://www.bicara.com
Analyst Forecast
According to 6 analyst ratings, the average rating for BCAX stock is "Buy." The 12-month stock price forecast is $40, which is an increase of 190.28% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago
+7.98%
Bicara Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
